STOCK REPORT · 950260 · KOSDAQ
INGENIA Therapeutics
Star it to add it to your market report.
Overall grade
50 pointsMiddle bandOverall 50 points · Grade B, 20 points to Grade A
Financial summary
INGENIA Therapeutics (950260) has an overall grade of B from financial statements, with a score of 50 out of 100. Category scores are Earnings 50 (Grade B), Financial health 50 (Grade B) and Dividends 50 (Grade B). Data as of Oct 23, 2026.
Valuation: Market cap ₩1.0T.
0 of the 9 graded metrics have values in this update.
The share price was collected from the Korea Exchange on Oct 23, 2026. How the grades are calculated is set out in the grading methodology.
This summary restates reported financial figures. It does not forecast share prices or returns.
Valuation
52-week range
Now at 54% of rangeWithin their own 52-week ranges, 86.7% of major Korean stocks sit lower than this one.
About these metrics
- Market cap
- Share price × shares outstanding. The value the market puts on the whole company.
- 52-week high
- The highest share price over the past year.
- 52-week low
- The lowest share price over the past year.
Scores by category
Each metric out of 100 · category score is the average of threeEarnings
40% of overall · Middle bandEach metric is scored out of 100, and the 50 above is the average of the three scores.
Metrics with values0 of 3
Metrics shown as - in the table are not measured in this update, because no data arrived.
About these metrics
- ROE
- Return on equity. How much profit the company made on its own capital (equity).
- Operating margin
- Operating profit as a share of revenue: what the core business keeps.
- Revenue growth
- How much revenue changed compared with a year earlier.
Financial health
35% of overall · Middle bandEach metric is scored out of 100, and the 50 above is the average of the three scores.
Metrics with values0 of 3
Metrics shown as - in the table are not measured in this update, because no data arrived.
About these metrics
- Debt-to-equity ratio
- Liabilities as a share of equity. A lower ratio means the company relies less on debt.
- Current ratio
- Assets that can turn into cash within a year, as a share of debts due within a year. At 100% or more they cover those debts.
- Interest coverage
- How many times operating profit covers interest expense. Below 1x, operating profit does not cover interest.
Dividends
25% of overall · Middle bandEach metric is scored out of 100, and the 50 above is the average of the three scores.
Metrics with values0 of 3
Metrics shown as - in the table are not measured in this update, because no data arrived.
About these metrics
- Dividend yield
- Dividends paid over a year as a share of the current share price.
- Payout ratio
- The share of profit paid out as dividends. A very high ratio can be hard to keep up.
- Dividend streak
- How many years in a row the company has paid a dividend.
Metric scores are shown rounded to one decimal place, so a category score can differ by up to 1 point from a plain average of the three shown.
| Metric | INGENIA Therapeutics | Sector median |
|---|---|---|
| PER | - | 34.3x |
| PBR | - | 6.7x |
| ROE | - | 9.2% |
| Operating margin | - | 13.0% |
| Debt-to-equity ratio | - | 54.9% |
| Dividend yield | - | 0.7% |
Grey values on the right are sector medians
Healthcare stocks close in market cap rank
Sector medians cover the 71 Healthcare stocks listed on Jupick. Typical levels differ by sector, so this is reference information for a simple comparison and not a basis for investment decisions.
About these metrics
- PER
- Price to earnings ratio (market cap ÷ annual net profit). A lower value means a lower price relative to profit.
- PBR
- Price to book ratio (market cap ÷ net assets). Below 1x, the market value is below book value.
- ROE
- Return on equity. How much profit the company made on its own capital (equity).
- Operating margin
- Operating profit as a share of revenue: what the core business keeps.
- Debt-to-equity ratio
- Liabilities as a share of equity. A lower ratio means the company relies less on debt.
- Dividend yield
- Dividends paid over a year as a share of the current share price.
Where this score sits
24.8% of the major stocks graded by Jupick score lower than this. Stocks in the same Grade B: 289.
- S172.8%
- A14524.2%
- BThis stock28948.2%
- C12621%
- D233.8%
The Grade B band runs from 50 to 69 points, 20 points wide. This stock's 50 points sit exactly on the lower boundary, and 20 points remain to 70, where Grade A starts.
Within the Healthcare sector alone, it ranks No. 50 of 71 stocks with an overall score, and the median overall score of the sector is 60.
Unlike metric values, the overall score uses the same baseline for every market and currency, so Korean and US stocks share one sample. The grade boundaries of 85, 70, 50 and 30 points apply equally to every stock, so the counts above are how the sample actually splits at those boundaries. Because one point can decide a grade, two stocks with different grades can be closer in score than two stocks with the same grade. The shares and ranks here describe only the major stocks Jupick covers, not every listed stock.
Stocks with similar score profiles
| Stock | Earnings | Financial health | Dividends |
|---|---|---|---|
| INGENIA Therapeutics (950260, this stock) | 50 | 50 | 50 |
| BAimed Bio | 50 | 50 | 50 |
| BKB Balhae Infrastructure Fund | 50 | 50 | 50 |
| BElice | 50 | 50 | 50 |
| BSamsung E&A | 49 | 51 | 60 |
INGENIA Therapeutics (950260) has category scores of Earnings 50 · Financial health 50 · Dividends 50. These are the four major stocks graded in all three categories whose profiles come closest, and no category differs by more than 10 points.
The three scores are given by Jupick from public financial metrics, each out of 100. A similar profile means similar grading results only. It does not mean the share prices move alike.
Where the share price enters the grade
The grade above turns 9 metrics into scores and combines them. Counting how many of them use the share price shows whether the grade moves when the price moves.
The 9 graded metrics stay the same when the share price moves.
- Earnings grade metrics (3)Does not use the share price0 of 3 metrics use the share price
- Financial health grade metrics (3)Does not use the share price0 of 3 metrics use the share price
- Dividends grade metrics (3)Does not use the share price0 of 3 metrics use the share price
- PER and PBRCome from the share price but are not scoredNot graded
For Korean stocks, Dividend yield is taken as stated in the disclosure, so it is not recalculated when the share price changes. What changes the grade is the next financial filing, not the share price.
Stocks with a value for each metric
The grade above uses 9 metrics. Each line shows how many major stocks have a value for that metric, so you can tell whether a blank is specific to this stock or common to most stocks.
None of the 9 graded metrics have values.
- ROENo data567 of 600 stocks have a valueMost stocks have a value
- Operating marginNo data562 of 600 stocks have a valueMost stocks have a value
- Revenue growthNo data570 of 600 stocks have a valueMost stocks have a value
- Debt-to-equity ratioNo data559 of 600 stocks have a valueMost stocks have a value
- Current ratioNo data545 of 600 stocks have a valueMost stocks have a value
- Interest coverageNo data278 of 600 stocks have a valueMore than half of stocks have no value
- Dividend yieldNo data519 of 600 stocks have a valueMost stocks have a value
- Payout ratioNo data507 of 600 stocks have a valueMost stocks have a value
- Dividend streakNo data595 of 600 stocks have a valueMost stocks have a value
Blank metrics on this stock: 1. Many other stocks are blank on them too.
Position in the market distribution
Korean stocksThis is where the Korean stocks on Jupick are lined up from the smallest value, ignoring sector. This time none of INGENIA Therapeutics's 6 metrics could be lined up, so there is no position to show. The reason is given for each metric below.
INGENIA Therapeutics metrics with no position on this page. Jupick does cover them, but they could not be lined up this time. The reason is given next to each.
- PER Could not be lined up this time
- PBR Could not be lined up this time
- ROE Could not be lined up this time
- Operating margin Could not be lined up this time
- Debt-to-equity ratio Could not be lined up this time
- Dividend yield Could not be lined up this time
Won and dollar stocks have different metric levels, so they are counted in separate samples. This is only where a value sits in a line-up, not a sign of good or bad and not an investment judgement. Stocks without the metric, and loss-making stocks where PER or PBR does not hold, are left out of the sample.
Next
Investment notice
For information only. Not investment advice. Grades and figures are reference material calculated from public information. They do not ask anyone to trade a security and make no promise of returns. You are solely responsible for your investment decisions and their results, and Jupick accepts no legal liability for them.